Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis (2024)

Daniels, K., van der Nat, P. B., Frequin, S. T. F. M., van der Wees, P. J., Biesma, D. H., Hoogervorst, E. L. J. (2020). Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International, 2020, Article 5463451. https://doi.org/10.1155/2020/5463451

Daniels, K ; van der Nat, P B ; Frequin, S T F M et al. / Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. In: Multiple Sclerosis International. 2020 ; Vol. 2020.

@article{f687cebb4ebb4069a719488f54706404,

title = "Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis",

abstract = "Background: Recently, ocrelizumab (Ocrevus{\textregistered}) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.",

author = "K Daniels and {van der Nat}, {P B} and Frequin, {S T F M} and {van der Wees}, {P J} and Biesma, {D H} and Hoogervorst, {E L J} and {van de Garde}, {E M W}",

note = "Copyright {\textcopyright} 2020 K. Daniels et al.",

year = "2020",

doi = "10.1155/2020/5463451",

language = "English",

volume = "2020",

journal = "Multiple Sclerosis International",

issn = "2090-2654",

publisher = "Hindawi Publishing Corporation",

}

Daniels, K, van der Nat, PB, Frequin, STFM, van der Wees, PJ, Biesma, DH, Hoogervorst, ELJ 2020, 'Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis', Multiple Sclerosis International, vol. 2020, 5463451. https://doi.org/10.1155/2020/5463451

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. / Daniels, K; van der Nat, P B; Frequin, S T F M et al.
In: Multiple Sclerosis International, Vol. 2020, 5463451, 2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

AU - Daniels, K

AU - van der Nat, P B

AU - Frequin, S T F M

AU - van der Wees, P J

AU - Biesma, D H

AU - Hoogervorst, E L J

AU - van de Garde, E M W

N1 - Copyright © 2020 K. Daniels et al.

PY - 2020

Y1 - 2020

N2 - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

AB - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

U2 - 10.1155/2020/5463451

DO - 10.1155/2020/5463451

M3 - Article

C2 - 32607256

SN - 2090-2654

VL - 2020

JO - Multiple Sclerosis International

JF - Multiple Sclerosis International

M1 - 5463451

ER -

Daniels K, van der Nat PB, Frequin STFM, van der Wees PJ, Biesma DH, Hoogervorst ELJ et al. Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International. 2020;2020:5463451. doi: 10.1155/2020/5463451